In 1996 was created Fresenius Medical Care, which is appeared as Corporate Investor. The venture was found in Europe in Germany. The main department of described Corporate Investor is located in the Homburg.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Fresenius Medical Care, startups are often financed by Zohar Gilon, California Institute for Regenerative Medicine, Amplify.LA. The meaningful sponsors for the fund in investment in the same round are Mitsubishi UFJ Capital, Grey Sky Venture Partners, ehuda Zisafe. In the next rounds fund is usually obtained by Pangaea Ventures, National Institutes of Health, Mitsubishi UFJ Capital.
The high activity for fund was in 2018. This Fresenius Medical Care works on 16 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in less than 2 deals per year. The real fund results show that this Corporate Investor is 30 percentage points more often commits exit comparing to other companies. The common things for fund are deals in the range of 10 - 50 millions dollars. The average startup value when the investment from Fresenius Medical Care is 500 millions - 1 billion dollars.
This organization was formed by Eduard Fresenius. The overall number of key employees were 25.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Corvidia, Tridiuum, Vectorious Medical Technologies Among the most successful fund investment fields, there are Genetics, Therapeutics. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has no exact preference in some founders of portfolio startups.
Related Funds
Fund Name | Location |
BCI Europe | - |
Bedrock Capital | New York, New York, United States |
Berlin.de | Berlin, Berlin, Germany |
BIA Digital Partners | Chantilly, United States, Virginia |
Brentwood Capital Advisors | Franklin, Tennessee, United States |
Equity.com | Missouri, St Louis, United States |
Fengate Real Asset Investments | Canada, Ontario, Toronto |
Fremont Ventures | California, San Francisco, United States |
HB Reavis | England, London, United Kingdom |
Indo-US Venture Partners | California, Santa Clara, United States |
National Grid Partners (NGP) | California, San Francisco, United States |
Numenta | California, Redwood City, United States |
Perion Investment Fund | Budapest, Hungary |
Spruce Capital Partners | California, San Francisco, United States |
Sympasis Innovation Capital | Baden-Wurttemberg, Ettlingen, Germany |
Tango Ventures | Maine, Northern Washington Co, United States |
Technology 9 Labs (T9L) | Delhi, India, New Delhi |
Techstars Montreal AI Accelerator | Canada, Montréal, Quebec |
Whitewater CDA | United States, Whitewater, Wisconsin |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Memo Therapeutics | $27M | 02 Nov 2023 | Zurich, Zurich, Switzerland | ||
Memo Therapeutics | $25M | 16 Feb 2022 | Zurich, Zurich, Switzerland | ||
SafeRide Health | 08 Nov 2021 | California, United States | |||
EGenesis | $100M | 07 Nov 2019 | Cambridge, Massachusetts, United States | ||
$25M | 09 Jul 2019 | Golden, Colorado, United States | |||
SafeRide Health | 20 Feb 2019 | California, United States | |||
Modulim | $7M | 23 Jan 2019 | Irvine, California, United States | ||
Tridiuum | $9M | 18 Dec 2018 | Philadelphia, Pennsylvania, United States | ||
Vectorious Medical Technologies | $2M | 16 Jul 2018 | Tel Aviv-Yafo, Tel Aviv District, Israel |
– eGenesis from Cambridge, Mass. develops human-compatible organs, tissues, and cells.
– The company raised $125m in Series C funding.
– Backers included Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee Investment Management, and Osage University Partners and existing investors Leaps by Bayer, Fresenius Medical Care Ventures, ARCH Venture Partners, Wellington Partners, Khosla Ventures, and Alta Partners.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Memo Therapeutics | $27M | 02 Nov 2023 | Zurich, Zurich, Switzerland | ||
Memo Therapeutics | $25M | 16 Feb 2022 | Zurich, Zurich, Switzerland | ||
SafeRide Health | 08 Nov 2021 | California, United States | |||
EGenesis | $100M | 07 Nov 2019 | Cambridge, Massachusetts, United States | ||
$25M | 09 Jul 2019 | Golden, Colorado, United States | |||
SafeRide Health | 20 Feb 2019 | California, United States | |||
Modulim | $7M | 23 Jan 2019 | Irvine, California, United States | ||
Tridiuum | $9M | 18 Dec 2018 | Philadelphia, Pennsylvania, United States | ||
Vectorious Medical Technologies | $2M | 16 Jul 2018 | Tel Aviv-Yafo, Tel Aviv District, Israel |